Key terms
About CARA
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CARA news
Apr 12
6:16am ET
Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment
Mar 28
6:00am ET
Analysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)
Mar 27
9:50am ET
Cara Therapeutics to host conference call
Mar 27
4:55am ET
Cara Therapeutics to host conference call
Mar 26
5:14pm ET
Cara Therapeutics to host conference call
Mar 22
4:23pm ET
Cara Therapeutics CMO Resigns for New Opportunity
Mar 08
1:00am ET
Cara Therapeutics Is Worried About This – Should You Be Worried Too?
Mar 07
10:29am ET
Biotech Alert: Searches spiking for these stocks today
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 06
6:19am ET
Cara Therapeutics price target lowered to $10 from $11 at Canaccord
Mar 05
5:55am ET
Cara Therapeutics: Promising Phase 2/3 Trial Progression Fuels Buy Rating
Mar 04
4:09pm ET
Cara Therapeutics: Cash and cash equivalents sufficient for operations into 2026
Mar 04
4:07pm ET
Cara Therapeutics reports Q4 EPS (59c), consensus (41c)
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Jan 23
7:45am ET
Strong Buy Recommendation for Cara Therapeutics Based on Promising Notalgia Paresthetica Program and Solid Financial Position
Jan 22
3:22pm ET
Strategic Restructuring and Focus on NP Program Justify Buy Rating for Cara Therapeutics
Jan 22
7:05am ET
Cara Therapeutics sees cash runway into 2026
Jan 22
7:04am ET
Cara Therapeutics CSO Frederique Menzaghi to depart
Jan 22
7:04am ET
Cara Therapeutics to discontinue Phase 3 program in advanced CKD
Jan 22
7:03am ET
Cara Therapeutics announces planned workforce reduction of up to 50%
Jan 22
7:02am ET
Cara Therapeutics prioritizes late-stage notalgia paresthetic program
No recent press releases are available for CARA
CARA Financials
Key terms
Ad Feedback
CARA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CARA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range